Journal letter questions credible size of GLP-1 remission effect in ulcerative colitis
The Inflammatory Bowel Diseases piece by Agargun and colleagues scrutinises how large a symptomatic remission benefit from GLP-1 receptor agonists is plausible.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 14 20:00 ETSource: Inflammatory bowel diseases
The wire
- 01Inflammatory Bowel Diseases published a piece on 15 October by Agargun, Isik, Bardak and co-authors asking how large a GLP-1 receptor agonist effect on symptomatic remission in ulcerative colitis is credible.
- 02Clinicians seeing IBD patients on incretin therapy are already fielding questions about whether these drugs change colitis activity rather than just weight.
- 03Only the citation is available here; the underlying effect estimates, study designs critiqued and author conclusions would need to be read in full before changing any practice.
From the source
Read at pubmed.ncbi.nlm.nih.govGLP-1 receptor agonists and symptomatic remission in ulcerative colitis: how large an effect is credible?
Inflammatory bowel diseases · 2026 Oct 15 · Agargun BF, Isik B, Bardak AE et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42885151/
